Substituted benzamides and methods of use thereof
US-2015252038-A1 · Sep 10, 2015 · US
Substituted benzamides and methods of use thereof
US10179767B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10179767-B2 |
| Application number | US-201615161085-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 20, 2016 |
| Priority date | May 22, 2015 |
| Publication date | Jan 15, 2019 |
| Grant date | Jan 15, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.
First claim
Opening claim text (preview).
We claim: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 3. The compound of claim 1 that is selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 that is selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 5. The compound of claim 1 that is: or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition comprising the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
of the thyroid hormones, e.g. T3, T4 · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Antiarrhythmics · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10179767B2 cover?
- The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.
- Who is the assignee on this patent?
- Genentech Inc, Xenon Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D211/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).